BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30116245)

  • 1. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
    Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
    Front Immunol; 2018; 9():1758. PubMed ID: 30116245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
    Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
    J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exhaustion of the CD8
    Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
    Front Immunol; 2018; 9():446. PubMed ID: 29563914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
    Cohen JI
    Front Immunol; 2018; 9():237. PubMed ID: 29599765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
    Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
    J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.
    Buchbinder D; Seppanen M; Rao VK; Uzel G; Nugent D
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e319-e322. PubMed ID: 29200144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
    Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
    Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
    [No Abstract]   [Full Text] [Related]  

  • 11. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
    Carpier JM; Lucas CL
    Front Immunol; 2017; 8():2005. PubMed ID: 29387064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.
    Lucas CL; Kuehn HS; Zhao F; Niemela JE; Deenick EK; Palendira U; Avery DT; Moens L; Cannons JL; Biancalana M; Stoddard J; Ouyang W; Frucht DM; Rao VK; Atkinson TP; Agharahimi A; Hussey AA; Folio LR; Olivier KN; Fleisher TA; Pittaluga S; Holland SM; Cohen JI; Oliveira JB; Tangye SG; Schwartzberg PL; Lenardo MJ; Uzel G
    Nat Immunol; 2014 Jan; 15(1):88-97. PubMed ID: 24165795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
    Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
    J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
    Liu H; Tang XL; Liu JR; Li HM; Zhao SY
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
    Li GM; Liu HM; Guan WZ; Xu H; Wu BB; Feng JY; Sun L
    Medicine (Baltimore); 2019 May; 98(18):e15329. PubMed ID: 31045771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
    Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
    Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
    Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.